Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus rituximab versus placebo plus rituximab in untreated follicular lymphoma
NL-OMON54492Phase 3Active, not recruiting
- Sponsor
- Pharmacyclics
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing Ibrutinib plus rituximab with Placebo plus rituximab (2 arms). Primary endpoint: Progression-free survival. Started Aug 2018; status: active, not recruiting.
02
Drugs
ibrutinibrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON54492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54492.